Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.

Sultan SR, Millar SA, England TJ, O'Sullivan SE.

Front Pharmacol. 2017 Feb 24;8:81. doi: 10.3389/fphar.2017.00081. eCollection 2017.

2.

Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation.

Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, Haskó G, Čiháková D, Mechoulam R, Pacher P.

Mol Med. 2016 Jan 8. doi: 10.2119/molmed.2016.00007. [Epub ahead of print]

3.

Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors.

Hind WH, England TJ, O'Sullivan SE.

Br J Pharmacol. 2016 Mar;173(5):815-25. doi: 10.1111/bph.13368. Epub 2016 Feb 3.

4.

Neuroinflammatory responses in diabetic retinopathy.

Yu Y, Chen H, Su SB.

J Neuroinflammation. 2015 Aug 7;12:141. doi: 10.1186/s12974-015-0368-7. Review.

5.

Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation.

Stanley CP, Hind WH, Tufarelli C, O'Sullivan SE.

Cardiovasc Res. 2015 Sep 1;107(4):568-78. doi: 10.1093/cvr/cvv179. Epub 2015 Jun 19.

6.

Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.

Hegde VL, Singh UP, Nagarkatti PS, Nagarkatti M.

J Immunol. 2015 Jun 1;194(11):5211-22. doi: 10.4049/jimmunol.1401844. Epub 2015 Apr 27.

7.

Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.

Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, Lee WS, Haskó G, Mechoulam R, Pacher P.

Mol Med. 2015 Jan 6;21:38-45. doi: 10.2119/molmed.2014.00261.

8.

Resveratrol ameliorates high glucose and high-fat/sucrose diet-induced vascular hyperpermeability involving Cav-1/eNOS regulation.

Peng XL, Qu W, Wang LZ, Huang BQ, Ying CJ, Sun XF, Hao LP.

PLoS One. 2014 Nov 24;9(11):e113716. doi: 10.1371/journal.pone.0113716. eCollection 2014.

9.

Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers.

Li X, Fang P, Mai J, Choi ET, Wang H, Yang XF.

J Hematol Oncol. 2013 Feb 25;6:19. doi: 10.1186/1756-8722-6-19. Review.

10.

Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells.

Zhu M, Chen J, Jiang H, Miao C.

Cardiovasc Diabetol. 2013 Jan 11;12:13. doi: 10.1186/1475-2840-12-13.

11.

Role of adenosine in diabetic retinopathy.

Liou GI, Ahmad S, Naime M, Fatteh N, Ibrahim AS.

J Ocul Biol Dis Infor. 2011 Jun;4(1-2):19-24. doi: 10.1007/s12177-011-9067-5. Epub 2012 Jan 11.

12.

Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpesvirus-infected endothelium.

Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE.

Genes Cancer. 2012 Jul;3(7-8):512-20. doi: 10.1177/1947601912466556.

13.

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review.

14.

Epigallocatechin gallate reduces vascular inflammation in db/db mice possibly through an NF-κB-mediated mechanism.

Babu PV, Si H, Liu D.

Mol Nutr Food Res. 2012 Sep;56(9):1424-32. doi: 10.1002/mnfr.201200040. Epub 2012 Jul 2.

15.

ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.

Li H, Peng W, Jian W, Li Y, Li Q, Li W, Xu Y.

Cardiovasc Diabetol. 2012 Jun 13;11:65. doi: 10.1186/1475-2840-11-65.

16.

Is the cardiovascular system a therapeutic target for cannabidiol?

Stanley CP, Hind WH, O'Sullivan SE.

Br J Clin Pharmacol. 2013 Feb;75(2):313-22. doi: 10.1111/j.1365-2125.2012.04351.x. Review.

17.

Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.

Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC.

BMJ Open. 2012 Feb 24;2:e000494. doi: 10.1136/bmjopen-2011-000494. Print 2012.

18.

The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.

Horváth B, Mukhopadhyay P, Haskó G, Pacher P.

Am J Pathol. 2012 Feb;180(2):432-42. doi: 10.1016/j.ajpath.2011.11.003. Epub 2011 Dec 5. Review.

19.

Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE.

Br J Pharmacol. 2012 Apr;165(8):2598-610. doi: 10.1111/j.1476-5381.2011.01589.x.

20.

Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.

Liou GI.

World J Diabetes. 2010 Mar 15;1(1):12-8. doi: 10.4239/wjd.v1.i1.12.

Supplemental Content

Support Center